Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 532-542

  Haddad, Yasmine ^a   Choi, Woonyoung ^a   McConkey, David J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA CRYSTALLIN; DELTA CRYSTALLIN ENHANCER BINDING FACTOR 1; ERLOTINIB; MOLECULAR MARKER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL CYCLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG DOSE INCREASE; DRUG SENSITIVITY; GENE CONTROL; GENETIC HETEROGENEITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRESSOR GENE; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA;

CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DELTA-CRYSTALLINS; DRUG RESISTANCE, NEOPLASM; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HOMEODOMAIN PROTEINS; HUMANS; MESODERM; PHENOTYPE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS;

EID: 59449092007     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1733     Document Type: Article

References (31)

1. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72.
2. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24: 2659-65.
3. Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 2001;28: 56-66.
4. Di Gennaro E, Barbarino M, Bruzzese F, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ("Iressa"), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003;195:139-50.
5. Eberhard DA, Giaccone G, Johnson BE. Bio-markers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26: 983-94.
6. Heymach JV, Nilsson M, Blumenschein G, Papadimi-trakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 2006;12: 4441-5s.
7. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelialphenotype? Nat Rev Cancer 2007;7:415-28.
8. Eger A, Aigner K, Sonderegger S, et al. Delta EF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005;24:2375-85.
9. Frederick BA, Helfrich BA, Coldren CD, et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007;6:1683-91.
10. Black PC, Brown GA, InamotoT, et al. Sensitivity to epidermal growth factor receptor inhibitor requires Ecadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008;14:1478-86.
11. Shrader M, Pino MS, Brown G, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol CancerTher 2007;6:277-85.
12. Pino MS, Shrader M, Baker CH, et al. Transforming growth factor α expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res 2006;66: 3802-12.
13. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11: 8686-98.
14. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298:70-82.
15. Barr S, Thomson S, Buck E, et al. Bypassing cellular EGF receptor dependence through epithelial-to-mes-enchymal-like transitions. Clin Exp Metastasis 2008; 25:685-93.
16. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944-50.
17. Wilding J, Vousden KH, Soutter WP, McCrea PD, Del Buono R, Pignatelli M. E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Res 1996;56: 5285-92.
18. Qian X, KarpovaT, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 2004;23:1739-48.
19. Takahashi K, Suzuki K, Tsukatani Y Induction of tyrosine phosphorylation and association of β-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence. Oncogene 1997;15:71 -8.
20. Dumstrei K, Wang F, Shy D, Tepass U, Hartenstein V. Interaction between EGFR signaling and DE-cadherin during nervous system morphogenesis. Development 2002;129:3983-94.
21. Lo HW, Hsu SC, Xia W, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 2007;67: 9066-76.
22. Lu Z, Ghosh S, Wang Z, Hunter T. Down-regulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of (β-catenin, and enhanced tumor cell invasion. Cancer Cell 2003;4:499-515.
23. Chung CH, Parker JS, Ely K, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006;66:8210-8.
24. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22: 894-907.
25. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMTand invasion in cancer cells. EMBO Rep 2008;9:582-9.
26. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
27. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007; 67:7972-6.
28. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84-90.
29. Garber K. HDAC inhibitors overcome first hurdle. Nat Biotechnol 2007;25:17-9.
30. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 2007;6:21 -2.
31. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247-52.